Driehaus Capital Management LLC Takes $6.92 Million Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Driehaus Capital Management LLC purchased a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) in the second quarter, Holdings Channel.com reports. The fund purchased 102,909 shares of the medical instruments supplier’s stock, valued at approximately $6,924,000.

Several other large investors have also added to or reduced their stakes in the stock. Harbor Capital Advisors Inc. purchased a new stake in shares of LeMaitre Vascular in the 2nd quarter worth about $26,000. Congress Wealth Management LLC DE lifted its stake in shares of LeMaitre Vascular by 541.7% in the 2nd quarter. Congress Wealth Management LLC DE now owns 74,722 shares of the medical instruments supplier’s stock valued at $5,027,000 after purchasing an additional 63,078 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of LeMaitre Vascular during the first quarter valued at approximately $1,014,000. Ellsworth Advisors LLC purchased a new stake in LeMaitre Vascular in the second quarter worth $415,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of LeMaitre Vascular by 0.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 244,181 shares of the medical instruments supplier’s stock valued at $16,428,000 after buying an additional 1,699 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $54.01 on Wednesday. LeMaitre Vascular, Inc. has a one year low of $43.69 and a one year high of $68.67. The stock has a 50-day moving average of $51.38 and a 200 day moving average of $57.85. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of 44.64, a PEG ratio of 2.98 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last issued its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.33 EPS for the quarter, topping the consensus estimate of $0.31 by $0.02. LeMaitre Vascular had a return on equity of 9.83% and a net margin of 14.69%. The company had revenue of $47.40 million during the quarter, compared to analyst estimates of $47.58 million. During the same quarter in the previous year, the company posted $0.25 earnings per share. LeMaitre Vascular’s revenue was up 21.5% compared to the same quarter last year. On average, equities analysts predict that LeMaitre Vascular, Inc. will post 1.34 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, November 30th. Stockholders of record on Thursday, November 16th were paid a $0.14 dividend. The ex-dividend date of this dividend was Wednesday, November 15th. This represents a $0.56 annualized dividend and a dividend yield of 1.04%. LeMaitre Vascular’s dividend payout ratio (DPR) is 46.28%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. StockNews.com upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Thursday, November 30th. Oppenheimer initiated coverage on LeMaitre Vascular in a research note on Tuesday, September 5th. They issued an “outperform” rating and a $70.00 target price on the stock. Finally, JMP Securities assumed coverage on LeMaitre Vascular in a research report on Monday, October 23rd. They issued an “outperform” rating and a $60.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average price target of $67.60.

View Our Latest Analysis on LeMaitre Vascular

About LeMaitre Vascular

(Free Report)

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

See Also

• Five stocks we like better than LeMaitre Vascular
• Large Cap Stock Definition and How to Invest
• Skechers sprints to a record high, still has room to run
• Investing in the High PE Growth Stocks
• Grab Starbucks on the dip before coffee futures fall
• What is Forex and How Does it Work?
• Simply Good Foods: Winner in the Ozempic Weight-Loss Trend

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report).